search
Back to results

Dietary Polyphenols and Insulin Sensitivity in Overweight and Obese Humans

Primary Purpose

Healthy

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
EGCG+RSV-supplementation
Placebo
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy focused on measuring Polyphenols, Resveratrol, Epigallocatechin-gallate, Insulin sensitivity, mitochondrial function, lipid oxidation, tissue lipolysis

Eligibility Criteria

20 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Overweight men and women (BMI≥25kg/m2-39.9kg/m2),
  • Aged 20-35 and 35-50 years
  • Caucasian
  • Normal fasting glucose (< 6.1 mmol/L) and normal postprandial glucose (2h-glucose <7.8 mm)
  • Normal blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg)
  • Weight stable in last 3 months (± 2kg)

Exclusion Criteria:

  • Women lactating, pregnant or (post) menopausal
  • Regular smokers
  • People with intensive fitness training, eg. athletes (≥ 3 per week ≥ 1 hour training)
  • Habitual consumption of green tea (more than 1 cup per day) or products containing green tea extract
  • Total caffeine consumption > 300 mg/day (1 can of cola or 2 cups of regular coffee or 2 cups of black tea or 1 cup of coffee and 1 cup of black tea or other combinations)
  • Alcohol intake >20 g/day (2 glasses of beer or wine)
  • Any dietary vitamins or dietary supplements
  • Diabetes mellitus (defined as FPG ≥ 7.0 mmol/l and/or 2hPG ≥ 11.1 mmol/l)
  • Serious pulmonary, cardiovascular, hepatic or renal disease
  • History of cardiovascular disease
  • All other relevant medical disorders that potentially interfere with this trial (e.g. history of gastro-intestinal, liver or thyroid disorders)
  • Current use of medication interfering with study intervention or interfering with study endpoints/hypotheses (e.g. medication containing caffeine like analgesics, anorectics and analeptics)
  • Not to be able to understand the study information
  • Subjects on a special diet or vegetarian
  • Blood donation 2 months prior to the study and during the study
  • Participation in other studies
  • Drug use
  • Coagulation disorders (i.e. hemophilia (type A, B and C), von Willebrand disease, vitamin K deficiency, afibrinogenemia, disseminated intravascular coagulation and thrombosis)
  • Use of anti-coagulant medication
  • Acute or history of gastrointestinal diseases (Morbus Crohn, Colitis Ulcerosa)
  • Intake of Antibiotics for the last 3 months

Sites / Locations

  • Maastricht University

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

EGCG+RSV-supplementation

Arm Description

micro-cellulose-filled Placebo

EGCG+RSV: 300mg/d + 80mg/d

Outcomes

Primary Outcome Measures

Systemic insulin sensitivity
hyperinsulinemic euglycemic clamp with glucose-tracer

Secondary Outcome Measures

skeletal muscle mitochondrial function
ex vivo skeletal muscle respiratory capacity

Full Information

First Posted
August 20, 2013
Last Updated
September 3, 2018
Sponsor
Maastricht University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02381145
Brief Title
Dietary Polyphenols and Insulin Sensitivity in Overweight and Obese Humans
Official Title
Long-term Supplementation of Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this double-blind, randomized, placebo-controlled study, we aim to investigate the effects of a long-term supplementation on insulin sensitivity, mitochondrial function and substrate metabolism in healthy overweight men and women. In each group, 21 subjects consume 100mg Resveratrol (RSV) and 150mg Epigallocatechin-gallate (EGCG), respectively Placebo capsules, twice daily over a period of 12 weeks. The subjects receive the capsules after the last pre-measurement and continue to take them throughout the post-measurements. Before and after the supplementation period, we perform a hyperinsulinemic-euglycemic clamp with a glucose-tracer infusion to assess hepatic and systemic insulin sensitivity. Simultaneously, substrate oxidation is measured throughout the clamp by indirect calorimetry. Furthermore, we perform a high-fat mixed meal test, in which we collect blood and measure substrate oxidation during fasted and postprandial conditions. During the meal tests, extra plasma is collected at the start (t=-30) and the end (t=240), of which the supernatant is stored in light-protected tubes (EGCG is mixed 1:1 with an EGCG buffer) for analyzing polyphenol concentrations in the blood. In the male subgroup (21 men), we additionally place each 2 microdialysis probes in the subcutaneous adipose tissue and the gastrocnemius in order to assess local lipolysis and blood flow by means of ethanol infusion. Furthermore, a dexa-scan is performed to assess body composition and biopsies are taken under fasted conditions from the subcutaneous adipose tissue and the quadriceps femoralis muscle. These samples are stored at -80C. Part of the adipose tissue samples is collected to measure adipocyte size. Of the skeletal muscle biopsy, one part is directly buffered and used for the oxygraph to measure mitochondrial function. At last, feces samples are collected before and after the intervention in order to assess energy content, microbial composition and short-chain fatty acid content. Based on previous human studies in our and other departments, we hypothesize that after 12 weeks of the combined polyphenol supplementation, insulin sensitivity and mitochondrial function improve. Furthermore, based on results of a short-term study performed by our group, that demonstrated an increase in energy expenditure, a positive effect on the regulation of body composition might be expected.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Polyphenols, Resveratrol, Epigallocatechin-gallate, Insulin sensitivity, mitochondrial function, lipid oxidation, tissue lipolysis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
micro-cellulose-filled Placebo
Arm Title
EGCG+RSV-supplementation
Arm Type
Active Comparator
Arm Description
EGCG+RSV: 300mg/d + 80mg/d
Intervention Type
Dietary Supplement
Intervention Name(s)
EGCG+RSV-supplementation
Other Intervention Name(s)
Teavigo, Pure Encapsulations Inc. (Massachusetts, USA), Resveratrol, Pure Encapsulations Inc. (Massachusetts, USA)
Intervention Description
Teavigo (~300mg/d) Resveratrol (~80mg/d)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Systemic insulin sensitivity
Description
hyperinsulinemic euglycemic clamp with glucose-tracer
Time Frame
change from week 0 to week 12 after supplementation
Secondary Outcome Measure Information:
Title
skeletal muscle mitochondrial function
Description
ex vivo skeletal muscle respiratory capacity
Time Frame
change from week 0 to week 12 after supplementation
Other Pre-specified Outcome Measures:
Title
lipid oxidation
Description
fasting and 4-h postprandial (high-fat mixed-meal) by indirect calorimetry
Time Frame
change from week 0 to week 12 after supplementation
Title
skeletal muscle and adipose tissue lipolysis
Description
microdialysate sample fasting and postprandial (after high-fat mixed-meal)
Time Frame
change from week 0 to week 12 after supplementation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Overweight men and women (BMI≥25kg/m2-39.9kg/m2), Aged 20-35 and 35-50 years Caucasian Normal fasting glucose (< 6.1 mmol/L) and normal postprandial glucose (2h-glucose <7.8 mm) Normal blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg) Weight stable in last 3 months (± 2kg) Exclusion Criteria: Women lactating, pregnant or (post) menopausal Regular smokers People with intensive fitness training, eg. athletes (≥ 3 per week ≥ 1 hour training) Habitual consumption of green tea (more than 1 cup per day) or products containing green tea extract Total caffeine consumption > 300 mg/day (1 can of cola or 2 cups of regular coffee or 2 cups of black tea or 1 cup of coffee and 1 cup of black tea or other combinations) Alcohol intake >20 g/day (2 glasses of beer or wine) Any dietary vitamins or dietary supplements Diabetes mellitus (defined as FPG ≥ 7.0 mmol/l and/or 2hPG ≥ 11.1 mmol/l) Serious pulmonary, cardiovascular, hepatic or renal disease History of cardiovascular disease All other relevant medical disorders that potentially interfere with this trial (e.g. history of gastro-intestinal, liver or thyroid disorders) Current use of medication interfering with study intervention or interfering with study endpoints/hypotheses (e.g. medication containing caffeine like analgesics, anorectics and analeptics) Not to be able to understand the study information Subjects on a special diet or vegetarian Blood donation 2 months prior to the study and during the study Participation in other studies Drug use Coagulation disorders (i.e. hemophilia (type A, B and C), von Willebrand disease, vitamin K deficiency, afibrinogenemia, disseminated intravascular coagulation and thrombosis) Use of anti-coagulant medication Acute or history of gastrointestinal diseases (Morbus Crohn, Colitis Ulcerosa) Intake of Antibiotics for the last 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ellen E Blaak, Prof.
Organizational Affiliation
Maastricht University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University
City
Maastricht
ZIP/Postal Code
6229 ER
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
30830386
Citation
Fazelzadeh P, Hoefsloot HCJ, Hankemeier T, Most J, Kersten S, Blaak EE, Boekschoten M, van Duynhoven J. Global testing of shifts in metabolic phenotype. Metabolomics. 2018 Oct 4;14(10):139. doi: 10.1007/s11306-018-1435-8.
Results Reference
derived
PubMed Identifier
28618864
Citation
Most J, Goossens GH, Reijnders D, Canfora EE, Penders J, Blaak EE. Gut microbiota composition strongly correlates to peripheral insulin sensitivity in obese men but not in women. Benef Microbes. 2017 Aug 24;8(4):557-562. doi: 10.3920/BM2016.0189. Epub 2017 Jun 16.
Results Reference
derived
PubMed Identifier
27194304
Citation
Most J, Timmers S, Warnke I, Jocken JW, van Boekschoten M, de Groot P, Bendik I, Schrauwen P, Goossens GH, Blaak EE. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr. 2016 Jul;104(1):215-27. doi: 10.3945/ajcn.115.122937. Epub 2016 May 18.
Results Reference
derived

Learn more about this trial

Dietary Polyphenols and Insulin Sensitivity in Overweight and Obese Humans

We'll reach out to this number within 24 hrs